Current concepts in the diagnosis and management of cytokine release syndrome - PubMed (original) (raw)
Case Reports
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W Lee et al. Blood. 2014.
Erratum in
- Blood. 2015 Aug 20;126(8):1048. Dosage error in article text
- Erratum: Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188-195.
[No authors listed] [No authors listed] Blood. 2016 Sep 15;128(11):1533. doi: 10.1182/blood-2016-07-730689. Blood. 2016. PMID: 31265503 Free PMC article.
Abstract
As immune-based therapies for cancer become potent, more effective, and more widely available, optimal management of their unique toxicities becomes increasingly important. Cytokine release syndrome (CRS) is a potentially life-threatening toxicity that has been observed following administration of natural and bispecific antibodies and, more recently, following adoptive T-cell therapies for cancer. CRS is associated with elevated circulating levels of several cytokines including interleukin (IL)-6 and interferon γ, and uncontrolled studies demonstrate that immunosuppression using tocilizumab, an anti-IL-6 receptor antibody, with or without corticosteroids, can reverse the syndrome. However, because early and aggressive immunosuppression could limit the efficacy of the immunotherapy, current approaches seek to limit administration of immunosuppressive therapy to patients at risk for life-threatening consequences of the syndrome. This report presents a novel system to grade the severity of CRS in individual patients and a treatment algorithm for management of CRS based on severity. The goal of our approach is to maximize the chance for therapeutic benefit from the immunotherapy while minimizing the risk for life threatening complications of CRS.
Figures
Figure 1
IL-6 signaling and inhibition by tocilizumab. (A) Classic IL-6 signaling restricted to IL-6R–expressing cells shown in pink (macrophages, neutrophils, T cells, and hepatocytes), which predominates when IL-6 levels are low. IL-6 binds to cell-associated IL-6R, leading to homodimerization of gp130 and initiation of downstream pathways. (B) Both classic and _trans_-IL-6 signaling, which occurs when IL-6 levels are elevated, leading to IL-6 signaling on a broad array of cells, because gp130 is ubiquitously expressed. Tocilizumab binding to both cell-associated IL-6R and soluble IL-6R inhibits classic and _trans_-signaling. IL-6R–expressing cells are shown in pink, whereas non-IL-6R–expressing cells are shown in blue.
Figure 2
Treatment algorithm for management of CRS based on the revised CRS grading system. The algorithm uses the revised grading system for CRS to direct clinical management for patients with immunotherapy-associated CRS. We recommend vigilant supportive care including empiric treatment of concurrent bacterial infections and maintenance of adequate hydration and blood pressure for every grade. Immunosuppression should be used in all patients with grade 3 or 4 CRS and instituted earlier in patients with extensive comorbidities or older age. Grades 2-4 organ toxicities are dictated by CTCAE v4.0.
Figure 3
Cytokine changes associated with clinical findings in a hypothetical patient with grade 3 CRS. A dramatic rise in IL-6 and IFNγ levels is associated with the onset of fever at day 3 after CAR T-cell infusion. Despite vigilant supportive care, the patient becomes hypotensive, requiring the use of 1 vasopressor on day 5. After a brief period of cardiovascular stability, a second vasopressor is required to maintain adequate perfusion on day 6, at which time tocilizumab is administered. IL-6 levels continue to rise transiently after tocilizumab, because it continues to be produced and tocilizumab blocks IL-6R-mediated endocytosis. Vasopressor support is gradually weaned over the next 48 hours, although neurologic changes may persist or initially manifest after tocilizumab, but eventually resolve. Several other inflammatory cytokines, including TNFα, IL-2, GM-CSF, and others noted in the text are also likely to be elevated during the peak of the syndrome.
Similar articles
- FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R. Le RQ, et al. Oncologist. 2018 Aug;23(8):943-947. doi: 10.1634/theoncologist.2018-0028. Epub 2018 Apr 5. Oncologist. 2018. PMID: 29622697 Free PMC article. - Cytokine release syndrome.
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS. Shimabukuro-Vornhagen A, et al. J Immunother Cancer. 2018 Jun 15;6(1):56. doi: 10.1186/s40425-018-0343-9. J Immunother Cancer. 2018. PMID: 29907163 Free PMC article. Review. - Management of cytokine release syndrome related to CAR-T cell therapy.
Chen H, Wang F, Zhang P, Zhang Y, Chen Y, Fan X, Cao X, Liu J, Yang Y, Wang B, Lei B, Gu L, Bai J, Wei L, Zhang R, Zhuang Q, Zhang W, Zhao W, He A. Chen H, et al. Front Med. 2019 Oct;13(5):610-617. doi: 10.1007/s11684-019-0714-8. Epub 2019 Sep 28. Front Med. 2019. PMID: 31571160 - Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.
Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, Fitzgerald JC, Aplenc R, Gore L, Grupp SA. Teachey DT, et al. Blood. 2013 Jun 27;121(26):5154-7. doi: 10.1182/blood-2013-02-485623. Epub 2013 May 15. Blood. 2013. PMID: 23678006 Free PMC article. - Cytokine release syndrome: Who is at risk and how to treat.
Frey N. Frey N. Best Pract Res Clin Haematol. 2017 Dec;30(4):336-340. doi: 10.1016/j.beha.2017.09.002. Epub 2017 Sep 22. Best Pract Res Clin Haematol. 2017. PMID: 29156206 Review.
Cited by
- Advancement and Challenges in Monitoring of CAR-T Cell Therapy: A Comprehensive Review of Parameters and Markers in Hematological Malignancies.
Ploch W, Sadowski K, Olejarz W, Basak GW. Ploch W, et al. Cancers (Basel). 2024 Sep 29;16(19):3339. doi: 10.3390/cancers16193339. Cancers (Basel). 2024. PMID: 39409959 Free PMC article. Review. - CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview.
Abdalhadi HM, Chatham WW, Alduraibi FK. Abdalhadi HM, et al. Int J Mol Sci. 2024 Sep 29;25(19):10511. doi: 10.3390/ijms251910511. Int J Mol Sci. 2024. PMID: 39408836 Free PMC article. Review. - S100 as marker for immune effector cell-associated neurotoxicity syndrome.
Schulenburg A, Rüsing LZ, Bumberger A, Mitterbauer M, Rabitsch W. Schulenburg A, et al. Wien Klin Wochenschr. 2024 Oct 4. doi: 10.1007/s00508-024-02451-0. Online ahead of print. Wien Klin Wochenschr. 2024. PMID: 39365474 - Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders.
Song Y, Li J, Wu Y. Song Y, et al. Signal Transduct Target Ther. 2024 Oct 4;9(1):263. doi: 10.1038/s41392-024-01952-8. Signal Transduct Target Ther. 2024. PMID: 39362875 Free PMC article. Review. - Acute estradiol and progesterone therapy in hospitalized adults to reduce COVID-19 severity: a randomized control trial.
Lovre D, Qadir MMF, Bateman K, Saltzman LY, Sherman M, Mauvais-Jarvis F. Lovre D, et al. Sci Rep. 2024 Sep 30;14(1):22732. doi: 10.1038/s41598-024-73263-5. Sci Rep. 2024. PMID: 39349554 Free PMC article. Clinical Trial.
References
- Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112(12):4371–4383. - PubMed
- Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443–446. - PubMed
- Kantoff PW, Higano CS, Shore ND, et al. IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials